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Purpose: Thirty percent of patients with postherpetic neuralgia (PHN) receiving conserva-
tive treatment report unsatisfactory pain relief. Epidural steroid injections (ESIs) are com-
monly used as a therapeutic intervention in these patients. In this study, we aimed to
determine if there are variables that predict the efﬁcacy of ESI in patients with PHN.
Patients and methods: We retrospectively identiﬁed patients seen at Mayo Clinic who
had PHN and received ESI. From their medical records, we abstracted the demographic
variables, concurrent medication use, anatomic approach and medication for ESI, and degree
of pain relief at 2 and 12 weeks' postintervention.
Results: None of the studied variables were signiﬁcantly associated with efﬁcacy of ESI in
patients with PHN. PHN that began <11 months before treatment was predictive of a response to
ESI at 12 weeks postintervention (positive predictive value, 55%). Patients who reported poor
ESI efﬁcacy 2 weeks after the intervention had a 94% chance of still having pain at 12 weeks.
Conclusion: For this cohort of patients with PHN being treated with ESI, no demographic
characteristics, concurrently used medications, or type of ESI were associated with ESI
treatment efﬁcacy at 2 or 12 weeks after the intervention.
Keywords: herpes zoster, intervention, neuropathy
Introduction
Postherpetic neuralgia (PHN), the most common complication of varicella zoster
virus reactivation, may cause serious clinical problems that severely impair quality of
life to an extent comparable to cancer, chronic obstructive pulmonary disease, AIDS,
and ﬁbromyalgia.1–4 The pain of PHN is severe and may result in anorexia, weight
loss, fatigue, depression, and insomnia; taken together, these factors negatively
impact work, quality of life, and social activities.5 PHN is caused by nerve damage
from a herpes zoster (HZ) infection; pathologically, patients may have primary
afferent neural body and axon degeneration, spinal cord atrophy, scarring of the
dorsal root ganglion, and loss of epidermal innervation.6,7 These changes contribute
to increased N-methyl-D-aspartate glutamate receptor–dependent excitability of
spinal dorsal horn neurons,8–10 which contribute to the neuropathic pain of PHN.
Noninvasive management practices, which are widely used for PHN, have not been
consistently effective.11,12 Invasive treatment options have been developed, including
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local inﬁltration, sympathetic nerve blocks, and intrathecal
injections. However, the reported efﬁcacy of the invasive
methods also is inconsistent.13–17
Epidural steroid injection (ESI) with the transforaminal
and interlaminar administration of steroids and local anes-
thetics is among the more common treatments for patients
with refractory PHN. However, its effectiveness is contro-
versial. To our knowledge, the only study investigating
factors associated with improved efﬁcacy of transforam-
inal ESI for PHN reported a symptom duration of
<3 months as the only signiﬁcant predictor of beneﬁt.18
The speciﬁc aims of the present study were to seek other
factors associated with the efﬁcacy of ESI in our patient
population with PHN and to report our experience for
therapeutic success with ESI.
Methods
The Mayo Clinic Institutional Review Board approved this
retrospective study.
We searched electronic health records to identify
patients with PHN managed by ESI who were seen at
Mayo Clinic (Arizona, Florida, and Rochester campuses)
from January 1, 1997, through April 1, 2018. PHN was
deﬁned as pain in the area of the eruption that persisted for
>90 days after the onset of the rash.19–22 The following
patient data were recorded: age, sex, comorbidities, con-
current medications, duration of PHN, anatomic approach
of ESI, medication used for ESI, number of blocks, treat-
ment date, and degree of pain relief at 2 and 12 weeks'
postintervention. Pain relief was noted in the records in
multiple ways: 1) as “good,” “moderate,” or “poor”; 2)
as percent pain relief; or 3) as a point reduction on a pain
scale (1–10, with 10 being severe pain). For records
showing percent pain relief or pain scales, we considered
up to 20% or a 2-point reduction as poor relief; 30–60% or
a 3- to 6-point reduction as moderate relief; and >70% or
at least a 7-point reduction as good relief. All patient-
speciﬁc identiﬁers were removed from the data set before
analysis.
Univariate logistic regression using the Firth penalized
likelihood approach23 was used to investigate the associa-
tion between patient characteristics, concurrent medication
use, type of intervention, and moderate-to-good pain relief
outcomes at 2 and 12 weeks' postintervention. Receiver
operating characteristic analysis and the Youden index
were used to establish the optimum cutoff point for PHN
duration that would be predictive of moderate-to-good
pain relief at 12 weeks. The statistical analysis was
completed using SAS software, version 9.3 (SAS
Institute Inc.,Cary, NC, USA).
Results
Our initial search of the electronic health records, using
the terms “epidural steroid injection” and “postherpetic
neuralgia,” yielded 528 medical records. The records
were reviewed, and we identiﬁed 42 patients meeting the
deﬁnition of PHN from reactivation of HZ who were
treated with ESI (54.8% male). Table 1 summarizes the
demographic and clinical characteristics of the patients.
We did not identify any signiﬁcant association between
moderate-to-good pain relief (at 2 or 12 weeks post-ESI)
and patient demographics, concurrent medication use, ESI
approach, or medications injected for the intervention
(Tables 2 and 3). Patients who reported poor ESI efﬁcacy
2 weeks after the intervention had a 94% chance of still
having pain at 12 weeks. Of the 24 patients who had
a moderate-to-good pain relief 2 weeks after ESI, 19
(79%) had persistent relief after 12 weeks. PHN duration
<11 months was predictive of moderate-to-good pain relief
at 12 weeks’ post-ESI, with a positive predictive value of
55.2% (Table 4).
Discussion
PHN is associated with an impaired quality of life, espe-
cially for elderly patients.24 Current American Academy
of Neurology guidelines13 for reducing PHN-associated
pain recommend TCA, anticonvulsants such as gabapen-
tin and pregabalin, opioids, and topical lidocaine.
However, at least 30% of patients with PHN have unsa-
tisfactory relief of pain with these suggested treatments.25
Hence, regional anesthetic procedures, including subcu-
taneous anesthetic and steroid injections, sympathetic and
intrathecal nerve blocks, and ESI, are often used for
management of PHN, even though these treatments are
not strongly evidence based.
Mixed results have been reported with subcutaneous
anesthetic plus steroid injections or sympathetic nerve
blocks in the management of PHN.13,14 Intrathecal injec-
tions have shown promise, but concerns regarding their
safety remain.11,13,14,26–30 The risk of arachnoiditis
reported with intrathecal injections likely will prevent
this treatment from becoming widely used.27,28,30
The role of ESI in established PHN is also controversial.
Although ESI can induce short-term (1-month) pain relief for
patients with acute HZ, it is not effective for preventing long-
term PHN.15Two studies by Forrest16,17 compared the effects
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of ESI in patients with 1) PHN lasting >6 months or 2)
posttraumatic neuralgia. He reported that the pain of PHN
was signiﬁcantly reduced by ESI with local anesthetics, but
the treatment was not as effective for patients with posttrau-
matic neuralgia. However, it is unclear whether an interlami-
nar or transforaminal approach was applied.
A case report by Mehta et al5 described a 64-year-
old man with refractory thoracic dermatome PHN, 1.5
years after HZ onset; 12 weeks after transforaminal ESI,
he had complete resolution of symptoms. Kwak et al18
suggested that the only factor positively associated with
the effectiveness of transforaminal ESI was a symptom
duration shorter than 12 weeks; factors such as patient
age, sex, severity of initial pain, number of nerve
blocks, or comorbidities such as diabetes mellitus or
malignancy were not associated with the effectiveness
of transforaminal ESI. Mixed reports have been pub-
lished describing the application of interlaminar ESI in
HZ and PHN.15,31,32
In our study, 97% of patients were treated with inter-
laminar ESI. We did not identify any factor that predicted
an increased likelihood of moderate-to-good pain relief
with interlaminar ESI at 2 and 12 weeks' postintervention.
However, we veriﬁed the overall effectiveness of the inter-
vention with ESI and noted a sustained beneﬁt when the
therapy was given to patients with PHN duration
<11 months.
A limitation of our study was that we had only
1 patient for whom a transforaminal approach was con-
ﬁrmed. The transforaminal approach delivers therapy close
to the site of inﬂammation of the targeted dorsal root
ganglion and spinal nerve, thereby possibly providing the
greatest potential for beneﬁt with limited systemic
impact.33,34 We are aware of no published studies that
have compared the effect of interlaminar and transforam-
inal ESI for PHN.
Our study was also limited by its retrospective design;
therefore, some aspects of data collection may have been
incomplete. A high number of our patients presented to
their primary care physicians at the time of HZ, and data
such as pain severity and antiviral and adjuvant treatment
determined at those consultations were not available for
review. Our sample size was small and the study may have
been underpowered.
Inherent risks of ESI include infection, bleeding,
and minor trauma along the course of the needle;
such risks must be acknowledged when considering
this treatment.35
In conclusion, this study is the ﬁrst to investigate
predictive factors associated with the efﬁcacy of inter-
laminar ESI in patients with PHN. PHN duration
<11 months was predictive of moderate-to-good pain
relief 12 weeks after ESI. Additionally, 80% of patients
Table 1 Demographics and clinical characteristics (N=42)
Characteristic Value
Age at the time of ﬁrst ESI, years
Mean (SD) 70.3 (15.4)
Median (range) 74 (16.0–91.0)
Female sex, n (%) 19 (45.2)
Diabetes mellitus, n (%) 5 (11.9)
Inﬂammatory disease, n (%) 12 (28.6)
Malignant disease, n (%) 8 (19.0)
Concurrent medication, n (%)a
Aspirin 3 (7.1)
Acetaminophen 2 (4.8)
Gabapentin 24 (57.1)
Local anesthetic 5 (11.9)
Opioid 13 (31.0)
SSRI or SNRI 2 (4.8)
Steroid 1 (2.4)
Tricyclic antidepressant 6 (14.3)
Location of cutaneous rash
Cervical 1 (2.4)
Extremity 2 (4.8)
Lumbar 5 (11.9)
Thoracic 34 (81.0)
Duration of postherpetic
neuralgia, median (range), months
4 (0–217)
ESI medication
Steroid only 15 (40.5)
Steroid + local anesthetic 22 (59.5)
No data 5
Approach of ESI
Interlaminar 37 (97.4)
Transforaminal 1 (2.6)
No data 4
Number of ESI treatments
Mean (SD) 1.2 (0.5)
Median (range) 1 (1–3)
Moderate-to-good pain relief after ESI
2 weeks 24 (57.1)
12 weeks 19 (45.2)
Note: aNo patient concurrently used a nonsteroidal anti-inﬂammatory drug.
Abbreviations: ESI, epidural steroid injection; SNRI, serotonin–norepinephrine
reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor.
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Table 2 Variables associated with moderate-to-good pain relief, 2 weeks after ESI
Variable Number of patients (%) Odds ratio (95% CI) P-value
Demographic variables
Age at ﬁrst intervention, years
≤60 4/9 (44) Reference
>60 20/33 (61) 1.86 (0.42–8.21) 0.38
Sex
Male 14/23 (61) Reference
Female 10/19 (53) 0.72 (0.21–2.47) 0.60
Diabetes mellitus
No 19/37 (51) Reference
Yes 5/5 (100) 10.44 (0.41–265.7) 0.15
Inﬂammatory disease
No 17/30 (57) Reference
Yes 7/12 (58) 1.05 (0.27–4.07) 0.94
Malignant disease
No 20/34 (59) Reference
Yes 4/8 (50) 0.71 (0.15–3.32) 0.66
Concurrent medicationsa
Aspirin
No 23/39 (59) Reference
Yes 1/3 (33) 0.42 (0.04–4.75) 0.48
Acetaminophen
No 23/40 (58) Reference
Yes 1/2 (50) 0.75 (0.04–12.77) 0.83
Gabapentin
No 10/18 (56) Reference
Yes 14/24 (58) 1.12 (0.33–3.84) 0.86
Local anesthetic
No 21/37 (57) Reference
Yes 3/5 (60) 1.07 (0.16–7.13) 0.94
Opioid
No 19/29 (66) Reference
Yes 5/13 (38) 0.35 (0.09–1.34) 0.12
SSRI or SNRI
No 24/40 (60) Reference
Yes 0/2 (0) 0.14 (0–5.86) 0.29
Steroid
No 24/41 (59) Reference
Yes 0/1 (0) 0.23 (0–23.01) 0.53
Tricyclic antidepressant
No 20/36 (56) Reference
Yes 4/6 (67) 1.45 (0.24–8.72) 0.68
(Continued)
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Table 2 (Continued).
Variable Number of patients (%) Odds ratio (95% CI) P-value
Symptoms and interventions
Level of ESI
Thoracal 19/29 (66) Reference
Cervical 1/2 (50) 0.54 (0.03–9.54) 0.76
Lumbar 4/7 (57) 0.69 (0.13–3.7) 0.95
ESI medication
Steroid only 11/15 (73) Reference
Steroid + local anesthetic 13/22 (59) 0.56 (0.14–2.28) 0.41
Approach of ESI
Interlaminar 23/37 (62) Reference
Transforaminal 1/1 (100) 1.87 (0.02–184.23) 0.78
Location of cutaneous rash
Thoracic 21/34 (62) Reference
Cervical 1/1 (100) 1.89 (0.01–183.7) 0.58
Extremity 1/2 (50) 0.63 (0.04–10.93) 0.92
Lumbar 1/5 (20) 0.21 (0.03–1.78) 0.23
Note: aNo patients concurrently used nonsteroidal anti-inﬂammatory drugs.
Abbreviations: ESI, epidural steroid injection; SNRI, serotonin–norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor.
Table 3 Variables associated with moderate-to-good pain relief, 12 weeks after ESI
Variable Number of patients (%) Odds ratio (95% CI) P-value
Demographic variables
Age at ﬁrst intervention, years
≤60 4/9 (44) Reference
>60 15/33 (45) 1.02 (0.23–4.50) 0.98
Sex
Male 10/23 (43) Reference
Female 9/19 (47) 1.16 (0.34–3.94) 0.80
Diabetes mellitus
No 16/37 (43) Reference
Yes 3/5 (60) 1.83 (0.28–12.11) 0.53
Inﬂammatory disease
No 14/30 (47) Reference
Yes 5/12 (42) 0.83 (0.22–3.22) 0.79
Malignant disease
No 15/34 (44) Reference
Yes 4/8 (50) 1.26 (0.27–5.88) 0.77
Concurrent medicationsa
Aspirin
No 18/39 (46) Reference
Yes 1/3 (33) 0.7 (0.06–7.85) 0.77
Acetaminophen
No 18/40 (45) Reference
(Continued)
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who reported moderate-to-good treatment efﬁcacy 2
weeks after ESI had continued efﬁcacy at 12 weeks.
However, none of the patient characteristics, concurrent
medications, or type of intervention administered were
associated with efﬁcacy of ESI in PHN. Future studies
are warranted to verify this observation. The
Table 3 (Continued).
Variable Number of patients (%) Odds ratio (95% CI) P-value
Demographic variables
Yes 1/2 (50) 1.22 (0.07–20.84) 0.89
Gabapentin
No 8/18 (44) Reference
Yes 11/24 (46) 1.05 (0.31–3.59) 0.93
Local anesthetic
No 18/37 (49) Reference
Yes 1/5 (20) 0.35 (0.04–2.94) 0.33
Opioid
No 14/29 (48) Reference
Yes 5/13 (38) 0.69 (0.18–2.62) 0.58
SSRI or SNRI
No 19/40 (48) Reference
Yes 0/2 (0) 0.22 (0.01–9.57) 0.43
Steroid
No 19/41 (46) Reference
Yes 0/1 (0) 0.38 (0–37.09) 0.68
Tricyclic antidepressant
No 15/36 (42) Reference
Yes 4/6 (67) 2.5 (0.41–15.05) 0.31
Symptoms and interventions
Level of ESI
Thoracal 15/29 (52) Reference
Cervical 3/7 (43) 0.94 (0.05–16.43) 0.95
Lumbar 1/2 (50) 0.73 (0.14–3.83) 0.78
ESI medication
Steroid only 8/15 (53) Reference
Steroid+local anesthetic 11/22 (50) 0.88 (0.24–3.28) 0.85
Approach of ESI
Interlaminar 18/37 (49) Reference
Transforaminal 1/1 (100) 3.22 (0.03–318.54) 0.61
Location of cutaneous rash
Thoracic 15/34 (44) Reference
Cervical 1/1 (100) 3.79 (0.04–370.99) 0.58
Extremity 1/2 (50) 1.26 (0.07–21.82) 0.91
Lumbar 2/5 (40) 0.9 (0.13–6.02) 0.62
Likelihood of treatment response based on duration of PHN
≤11 months 16/29 (55) Reference
>11 months 3/13 (23) 0.27 (0.06–1.17) 0.08
Note: aNo patients concurrently used nonsteroidal anti-inﬂammatory drugs.
Abbreviations: ESI, epidural steroid injection; PHN, postherpetic neuralgia; SNRI, serotonin–norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor.
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effectiveness of ESI in PHN is not dependent on patient
characteristics, concurrent medications, block numbers,
or type of ESI.
Abbreviation list
ESI, epidural steroid injection; HZ, herpes zoster; PHN,
postherpetic neuralgia.
Disclosure
All authors report no conﬂicts of interest in this work.
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